State Board of Administration of Florida Retirement System Takes $71,000 Position in Kezar Life Sciences, Inc. (NASDAQ:KZR)

State Board of Administration of Florida Retirement System bought a new stake in Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) in the 4th quarter, Holdings Channel.com reports. The firm bought 10,136 shares of the company’s stock, valued at approximately $71,000.

Several other institutional investors and hedge funds have also made changes to their positions in KZR. Great West Life Assurance Co. Can purchased a new stake in Kezar Life Sciences during the 3rd quarter valued at approximately $26,000. Tower Research Capital LLC TRC raised its stake in shares of Kezar Life Sciences by 88.9% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company’s stock worth $58,000 after buying an additional 3,190 shares in the last quarter. Robeco Institutional Asset Management B.V. purchased a new position in shares of Kezar Life Sciences during the 3rd quarter worth approximately $68,000. UBS Asset Management Americas Inc. purchased a new position in shares of Kezar Life Sciences during the 3rd quarter worth approximately $86,000. Finally, Delphia USA Inc. purchased a new position in shares of Kezar Life Sciences during the 3rd quarter worth approximately $92,000. 84.03% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Price Performance

Shares of NASDAQ:KZR opened at $3.02 on Wednesday. The business’s fifty day moving average price is $2.84 and its two-hundred day moving average price is $5.38. The stock has a market cap of $218.68 million, a PE ratio of -2.85 and a beta of 0.17. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.44 and a current ratio of 19.44. Kezar Life Sciences, Inc. has a one year low of $2.25 and a one year high of $11.02.

Kezar Life Sciences (NASDAQ:KZR – Get Rating) last issued its earnings results on Tuesday, March 14th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). On average, analysts forecast that Kezar Life Sciences, Inc. will post -1.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on KZR shares. William Blair reissued a “market perform” rating on shares of Kezar Life Sciences in a research note on Wednesday, March 15th. Wells Fargo & Company lowered their price target on Kezar Life Sciences from $14.00 to $13.00 in a report on Friday, May 12th. Finally, HC Wainwright lowered their price target on Kezar Life Sciences from $21.00 to $19.00 in a report on Friday, May 12th.

About Kezar Life Sciences

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.